A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not ...

The event-free survival benefit with perioperative pembrolizumab in early NSCLC depends on the post-neoadjuvant residual ...

Data from a Phase 3 study has revealed that ivonescimab demonstrates a statistically significant and clinically meaningful ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...

For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer ...

Read more about A study of active surveillance for small cell lung cancer that has a risk of spreading to the brain (PRIMALung study) A trial of chemoradiotherapy, pembrolizumab, and olaparib for ...

a randomized phase III trial of carboplatin- or cisplatin-pemetrexed-pembrolizumab versus carboplatin- or cisplatin-pemetrexed in 492 patients with stage IV nonsquamous non–small cell lung cancer ...

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell ...

IL-21-engineered NK cells offer superior safety and long-term control for glioblastoma, Merck halted 2 phase 3 KEYNOTE trials of pembrolizumab, and the MonumenTAL-1 trial data is discussed.

This trial is looking at a drug called UCB4594 by itself and in combination with other treatments for solid cancers that have spread (advanced cancer). Read more about A trial looking at a drug called ...

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for more than 80% of lung cancer cases. The treatment plan and goal of treatment depend on the stage of your ...